Maze officer may sell $623K in stock under Rule 144

Maze Therapeutics, Inc. (MAZE) received a notice under Rule 144 that officer Jason V. Coloma, through Morgan Stanley Smith Barney LLC, may sell up to 23,497 shares of common stock, with an indicated aggregate market value of $623,400, after September 2, 2026.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) received a notice under Rule 144 that officer Jason V. Coloma, through Morgan Stanley Smith Barney LLC, may sell up to 23,497 shares of common stock, with an indicated aggregate market value of $623,400, after September 2, 2026. The shares arise from restricted stock units that vested and settled on September 1, 2026, and the reported sale is mandated by Maze Therapeutics and includes shares needed to satisfy related tax withholding obligations. The notice also lists multiple recent sales of Maze common stock during the prior three months by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.

Key Figures

Shares to be sold under Rule 144: 23,497 shares Aggregate market value of planned sale: $623,400 Shares outstanding: 55,549,168 shares +3 more

6 metrics

Shares to be sold under Rule 144 23,497 shares Planned sale of Maze Therapeutics common stock by officer Jason V. Coloma

Aggregate market value of planned sale $623,400 Value associated with the 23,497 Maze common shares in the Form 144

Shares outstanding 55,549,168 shares Maze Therapeutics common stock outstanding as referenced in the notice

RSU vesting date September 1, 2026 Date restricted stock units vested and settled, giving rise to the shares

Recent sale by Coloma Family Trust (June 23, 2026) 23,865 shares for $621,673.70 One of several Maze common stock sales in the past three months

Recent sale by Coloma Family Trust (July 1, 2026) 31,908 shares for $956,526.67 Maze common stock sold by Coloma Family Trust during the past three months

Key Terms

Rule 144, restricted stock units, equity incentive award, tax withholding obligations

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"resulting from the vesting and settlement of restricted stock units granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

equity incentive award financial

"restricted stock units granted pursuant to an equity incentive award"

Equity incentive award is a grant of company ownership or the right to buy ownership—such as stock, restricted shares, or options—given to employees, executives, or directors as part of their pay. Investors care because these awards align workers’ interests with shareholders (like giving someone slices of a pie so they try to make the pie bigger), but they also dilute existing ownership and increase reported compensation costs, which can affect share value and earnings per share.

tax withholding obligations financial

"includes an amount necessary to satisfy tax withholding obligations resulting"

FAQ

What does the Form 144 filing disclose for MAZE?

It discloses that Jason V. Coloma, an officer of Maze Therapeutics, may sell up to 23,497 shares of common stock under Rule 144, arising from vested restricted stock units, with the sale mandated by the issuer and including shares for tax withholding.

How many MAZE shares are covered by this planned Rule 144 sale?

The notice covers up to 23,497 shares of Maze Therapeutics common stock, with an indicated aggregate market value of $623,400 as of the filing. These shares are linked to the vesting and settlement of restricted stock units on September 1, 2026.

When are the MAZE shares expected to be sold under this Form 144?

The Form 144 lists a proposed sale date of September 2, 2026 for the 23,497 shares of Maze Therapeutics common stock. The filing states that the reported sale was mandated by Maze Therapeutics and tied to restricted stock unit vesting.

What is the nature of the MAZE securities being sold by Jason V. Coloma?

The securities are common stock of Maze Therapeutics originating from the vesting and settlement of restricted stock units on September 1, 2026. The filing describes this as compensation under an equity incentive award.

How many MAZE shares are outstanding according to the Form 144?

The Form 144 lists 55,549,168 shares of Maze Therapeutics common stock outstanding. This represents the total outstanding shares as referenced in connection with the planned Rule 144 sale of 23,497 shares.

What recent MAZE stock sales are reported for related Coloma trusts?

Recent sales include, among others, 31,908 shares by the Coloma Family Trust on July 1, 2026 for proceeds of $956,526.67, and 31,908 shares on September 1, 2026 for $838,784.74, plus several smaller transactions by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:02 PM Accepted by SEC EDGAR 09/02/2026 - 07:02 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001676170
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MAZE THERAPEUTICS, INC.
SEC File Number	001-42490
Address of Issuer	171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	650-850-5070
Name of Person for Whose Account the Securities are To Be Sold	Jason V Coloma
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	23497	623400	55549168	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/01/2026	Restricted Stock Unit Vesting	Issuer			23497	09/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Coloma Family Trust DTD 06/27/2016 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	06/22/2026	1953	50780.93
The Coloma 2021 Irrevocable Trust DTD 09/20/2021 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	06/22/2026	2040	53040.00
Coloma Family Trust DTD 06/27/2016 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	06/23/2026	23865	621673.70
The Coloma 2021 Irrevocable Trust DTD 09/20/2021 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	07/01/2026	2593	77726.21
Coloma Family Trust DTD 06/27/2016 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	07/01/2026	31908	956526.67
The Coloma 2021 Irrevocable Trust DTD 09/20/2021 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	08/03/2026	2593	69329.14
Coloma Family Trust DTD 06/27/2016 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	08/03/2026	31908	852985.88
The Coloma 2021 Irrevocable Trust DTD 09/20/2021 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	09/01/2026	2593	68214.05
Coloma Family Trust DTD 06/27/2016 c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	09/01/2026	31908	838784.74

144: Remarks and Signature

Remarks	The reported sale was mandated by the Issuer and includes an amount necessary to satisfy tax withholding obligations resulting from the vesting and settlement of restricted stock units granted pursuant to an equity incentive award.
Date of Notice	09/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jason V. Coloma
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)